Addition of the experimental drug cediranib to standard chemotherapy improves tumor shrinkage and adds a modest improvement in progression-free survival for patients with cervical cancer that has recurred after treatment.
Research suggests the human papillomavirus (HPV) vaccine could prevent 90 percent of cervical malignancies.
Researchers found nine human papillomavirus (HPV) subtypes cause the majority of cervical cancers
Many women under 30 years of age do not recognize the symptoms of cervical cancer.
Researchers say a urine screening may be accurate at identifying human papillomavirus (HPV).
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|